Analysts at StockNews.com started coverage on shares of 22nd Century Group (NASDAQ:XXII – Get Free Report) in a research note issued on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.
22nd Century Group Stock Down 16.4 %
Shares of NASDAQ:XXII opened at $0.18 on Wednesday. 22nd Century Group has a 12-month low of $0.18 and a 12-month high of $15.84. The company’s 50 day moving average price is $0.47 and its two-hundred day moving average price is $3.62. The firm has a market cap of $1.49 million, a PE ratio of 0.00 and a beta of 1.41.
22nd Century Group (NASDAQ:XXII – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter. The company had revenue of $7.95 million for the quarter. 22nd Century Group had a negative return on equity of 380.39% and a negative net margin of 275.12%.
Hedge Funds Weigh In On 22nd Century Group
22nd Century Group Company Profile
22nd Century Group, Inc, a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands.
Read More
- Five stocks we like better than 22nd Century Group
- The Basics of Support and Resistance
- Why Lennar Stock Could Be the Best Play in the Housing Market
- What is the Euro STOXX 50 Index?
- 2 Energy Stocks Fueling the AI Datacenter Boom
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.